|
Sign In to gain access to subscriptions and/or personal tools.
|
Rodent Carcinogenicity Bioassay: Past, Present, and Future
Gary A. Boorman
Pathology Branch and Experimental Pathology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, North Carolina 27709
Robert R. Maronpot
Pathology Branch and Experimental Pathology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, North Carolina 27709
Scot L. Eustis
Pathology Branch and Experimental Pathology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, North Carolina 27709
Toxicity/carcinogenicity studies in rodents have played a pivotal role in identifying chemicals that are potentially hazardous to humans. In fact, nearly all of the known human carcinogens are also carcinogenic in 1 or more rodent species. During the past 20 yr the quality and consistency of rodent studies has improved considerably, and much has been learned about mechanisms whereby chemicals initiate or promote the carcinogenic process in rats and mice. The process of identifying chemicals that cause toxicity or carcinogenicity in rodents is quite well established, but the procedures for extrapolating this data for risk management decisions in the protection of human health have lagged far behind. While many would accept the assumptions that genotoxic chemicals that cause cancer in animals pose a cancer risk to humans and that genotoxic chemicals causing cancer at high doses pose a risk at lower doses, there is much less certainty with respect to nongenotoxic chemicals. The confusion about risk extrapolation for nongenotoxic chemicals has often lead to criticism of the hazard identification process for chemicals in general. There is increasing awareness of the complexity of the carcinogenic process that has made species extrapolation and dose extrapolation from rodent studies to humans more complex. Although newer molecular biological techniques and cell kinetic measurements offer exciting possibilities for better risk assessment, it is the combination of well- designed rodent studies with appropriate mechanistic studies that offers the best hope for regulatory decisions based on sound scientific principles.
Key Words: Hazard identification chemical carcinogenesis risk assessment rat mouse 2-yr studies
Toxicologic Pathology, Vol. 22, No. 2,
105-111 (1994)
DOI: 10.1177/019262339402200204

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. M. Elrick, J. A. Kramer, C. L. Alden, E. A. G. Blomme, R. T. Bunch, M. A. Cabonce, S. W. Curtiss, L. D. Kier, K. L. Kolaja, C. P. Rodi, et al.
Differential Display in Rat Livers Treated for 13 Weeks with Phenobarbital Implicates a Role for Metabolic and Oxidative Stress in Nongenotoxic Carcinogenicity
Toxicol Pathol,
January 1, 2005;
33(1):
118 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. MacDonald
Human Carcinogenic Risk Evaluation, Part IV: Assessment of Human Risk of Cancer from Chemical Exposure Using a Global Weight-of-Evidence Approach
Toxicol. Sci.,
November 1, 2004;
82(1):
3 - 8.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Takaoka, S. Sehata, T. Maejima, T. Imai, M. Tor, H. Satoh, K. Toyosawa, Z.-Y. Tanakamaru, T. Adachi, S. Hisada, et al.
Interlaboratory Comparison of Short-Term Carcinogenicity Studies Using CB6F1-rasH2 Transgenic Mice
Toxicol Pathol,
February 1, 2003;
31(2):
191 - 199.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sehata, T. Maejima, M. Watanabe, S. Ogata, T. Makino, K. Tanaka, S. Manabe, and M. Takaoka
Twenty-Six-Week Carcinogenicity Study of Chloroform in CB6F1 rasH2-Transgenic Mice
Toxicol Pathol,
April 1, 2002;
30(3):
328 - 338.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Boorman, J. K. Haseman, M. D. Waters, J. F. Hardisty, and R. C. Sills
Quality Review Procedures Necessary for Rodent Pathology Databases and Toxicogenomic Studies: The National Toxicology Program Experience
Toxicol Pathol,
January 1, 2002;
30(1):
88 - 92.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Cohen, D. Robinson, and J. MacDonald
Alternative Models for Carcinogenicity Testing
Toxicol. Sci.,
November 1, 2001;
64(1):
14 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. N. Anisimov, N. Y. Zavarzina, M. A. Zabezhinski, I. G. Popovich, O. A. Zimina, A. V. Shtylick, A. V. Arutjunyan, T. I. Oparina, V. M. Prokopenko, A. I. Mikhalski, et al.
Melatonin Increases Both Life Span and Tumor Incidence in Female CBA Mice
J. Gerontol. A Biol. Sci. Med. Sci.,
July 1, 2001;
56(7):
B311 - 323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Cohen
Alternative Models for Carcinogenicity Testing: Weight of Evidence Evaluations Across Models
Toxicol Pathol,
January 1, 2001;
29(1_suppl):
183 - 190.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gulezian, D. Jacobson-Kram, C. B. Mccullough, H. Olson, L. Recio, D. Robinson, R. Storer, R. Tennant, J. M. Ward, and D. A. Neumann
Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment
Toxicol Pathol,
May 1, 2000;
28(3):
482 - 499.
[Abstract]
[PDF]
|
 |
|
|
|